Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Tarsus Pharmaceuticals secures $125.0 million in oversubscribed Private Placement Equity Financing, led by Barclays with participation from TCGX and Bain Capital. The funds will support clinical development and corporate activities.
PUBLIC · TARSAug 06, 2026•3 days ago
Amount Raised
$125 Million
Round Type
Post-IPO Equity
IrvineManufacturingBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaInvestors
Vestal Point CapitalRtw InvestmentsSirenia Capital Management LpAdar1 Capital ManagementWellington ManagementBain Capital Life SciencesTcgx
Description
Tarsus Pharmaceuticals has entered into a securities purchase agreement for a $125.0 million PIPE financing, with participation from both existing and new investors. The financing includes the sale of common stock and pre-funded warrants. Funds will be used for clinical development and other corporate purposes. The deal is expected to close on August 7, 2026.
Related People
Suggested for you
3 contactsVerified contactsAziz, Chief Commercial Officer hidden
Funding Insights
Based on industry dataVC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech